NCT02588521View on ClinicalTrials.gov

A Study of AL-794 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses, and the Antiviral Activity of Multiple Doses in an Influenza Challenge Study

PHASE1CompletedINTERVENTIONAL
Enrollment

152

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

August 14, 2017

Study Completion Date

August 14, 2017

Conditions
Influenza
Interventions
DRUG

AL-794

OTHER

Placebo/Vehicle

Suspension vehicle without active drug

Trial Locations (1)

Unknown

Hammersmith Medicines Research Ltd (HMR), London

Sponsors
All Listed Sponsors
lead

Alios Biopharma Inc.

INDUSTRY

NCT02588521 - A Study of AL-794 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses, and the Antiviral Activity of Multiple Doses in an Influenza Challenge Study | Biotech Hunter | Biotech Hunter